ROCKVILLE, Md., Dec. 2, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the LD MICRO VI: Main Event Conference at 9:30 a.m. (PT) on Wednesday, December 4, 2013. The conference will be held December 3-5, 2013 at the Luxe Sunset Bel Air Hotel in Los Angeles.
(Logo: https://photos.prnewswire.com/prnh/20130522/MM19465LOGO)
A live webcast of Synthetic Biologics’ presentation may be accessed by logging onto the internet at http://wsw.com/webcast/ldmicro5/SYN. After the presentation, a replay will be archived and accessible for 30 days at the same website.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics’ website at www.therivabio.com.
To download Synthetic Biologics’ investor relations mobile device app, which allows users access to the Company’s SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.
SOURCE Synthetic Biologics, Inc.
Released December 2, 2013